An advisory panel backed six peptides for compounding after a lengthy hearing where staff tried to block progress without solid preparation. Participants note this advances the process only one non-binding step and does not equate to full FDA drug approval. High development costs make traditional approval unlikely for common peptides, leading companies toward patentable analogs instead.
What this discussion establishesWhether the original headline was misleading about the scope of approval
Nothing here is advice.
This is unexpected! Peptides seem to be getting broader acceptance in the mainstream, but since it's the US, financial interests are probably driving these choices.
FDA staff tried hard to prevent the approval. I saw much of the hearing myself, and it was lengthy and mostly depressing.
They put in effort to stop it but didn't bother researching for the hearing. A few comments were funny in a bad way and others quite alarming.
I nearly got a flashback to middle school social studies. The session felt like it was run by beginners. I anticipated hearing something like this peptide now prevented from being studied lacks sufficient human evidence to allow research, show us more human evidence before we decide on permitting possible human studies. Maybe exaggerating a tiny bit.
The FDA hasn't given approval to anything, so the situation remains the same. This was just an advisory group with no binding power. The headline is misleading.
It's accurate that the process advanced only one stage. However, the headline didn't claim the entire FDA approved it, nor did it mention only a portion. It simply referred to FDA Compounding Approvals. Perhaps it intended to indicate the committee's approval.
Makes sense because they had approval up until 2023.
Even if they end up as compounded items, none count as FDA-approved drugs with solid trials proving safety and effectiveness like most medicines require. That doesn't prove they fail to work, only that studies haven't been conducted, so certainty about their safety or results is missing.
No one will ever manage to get an ordinary peptide through FDA approval. Just search online for the reason, which involves the huge time and expense required.
That's the reason they create a patentable version, like the dropped MOTS-c analog CB-4211 or the approved tesamorelin. Extra credit when it has better pharmacokinetics.
If you have tried it, this topic is still open. Sign in to reply — it takes a minute.